Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
EN10 (RAINDO BLUE & TAPER) is a new Canadian clinical trial that is applying state-of-the-art molecular testing to classify post-surgery treatments in early-stage endometrial cancer.
The purpose of this study is to identify people at low risk of cancer recurrence based on the molecular features of their tumours. These individuals may safely receive less radiotherapy or may require no radiotherapy or chemotherapy after surgery.
The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative held their annual research workshop on December 1 & 2nd in Waikiki Hawaii. In addition to the main workshop, a satellite guidelines panel was conducted in conjunction with NANETS to develop consensus statements for predictive and prognostic biomarkers in metastatic NENs.
The San Antonio Breast Cancer Symposium (SABCS) is an annual event cosponsored by the AACR and UT Health San Antonio’s Mays Cancer Center. The meeting hosts about 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research. This international scientific symposium allows for the important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
American Society of Hematology Annual Meeting and Exposition is the world’s most comprehensive hematology event of the year. ASH is a professional society concerned with the causes and treatments of blood disorders.